

Anti-hRANKL-hIgA2

Human IgA2 neutralizing monoclonal antibody against human RANKL

Catalog code: hrankl-mab7

<https://www.invivogen.com/anti-hrankl-higa2>

For research use only, not for diagnostic or therapeutic use

Version 18K09-MM

PRODUCT INFORMATION

Contents: 100 µg purified Anti-hRANKL-hIgA2 monoclonal antibody (mAb), provided azide-free and lyophilized

Target: Human receptor activator of nuclear factor-κB ligand (hRANKL)

Source: CHO cells

Isotype: Human IgA2

Light chain type: Kappa

Purity: Peptide M purified

Formulation: 0.2 µm filtered solution 91 mM TRIS buffer with 91 mM glycine, 5% w/v saccharose and stabilizing agents

Tested applications: Flow cytometry

Antibody resuspension

Add 1 ml of sterile water to obtain a concentration of 0.1 mg/ml.

Storage and stability

- Product is shipped at room temperature. Store lyophilized antibody at -20°C. Lyophilized product is stable for 1 year when stored at -20°C.

- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding of Anti-hRANKL-hIgA2 to hRANKL has been confirmed using ELISA and neutralizing cellular assays.

- The complete sequence of this antibody has been verified.

- The absence of bacterial contamination, lipoproteins and endotoxins, has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

ANTIBODY ISOTYPE COLLECTION

For your research, InvivoGen offers an Anti-hRANKL antibody family consisting of 3 different Fc isotypes, (IgG1, IgG2, and IgA2). These mAbs vary in their potency to mediate effector functions, such as complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), as presented in the table below.

Effector function	IgG1	IgG2	IgA2
ADCC	++	+/-	+
ADCP	+++	+/-	+
CDC	++	+	-

DESCRIPTION

Anti-hRANKL-hIgA2 mAb features the constant region of the human IgA2 isotype and the variable region of Denosumab. The clinically approved antibody, Denosumab, is a fully human IgG2 mAb that targets the transmembrane and soluble form of hRANKL, a member of the tumor necrosis factor cytokine family¹. Denosumab binding to hRANKL blocks this cytokine interaction with its receptor RANK and the downstream signaling¹. RANKL-RANK signaling is essential for the formation, function, and survival of mature osteoclasts, which are responsible for bone resorption. RANKL also has important functions in the immune system where it plays a pivotal role in dendritic cell maturation and in T-cell differentiation². Denosumab has been approved by the FDA for the treatment of osteoporosis and bone metastasis.

Anti-hRANKL-hIgA2 can be used in comparison with other anti-hRANKL mAbs to assess differences in the effector functions between isotypes. The IgA2 isotype is found predominantly in mucosal tissues. IgA2 is highly resistant to enzymatic degradation by bacterial proteases, due to a short hinge region. IgA2 displays no CDC, low ADCP and low ADCC.

Anti-hRANKL-hIgA2 was generated by recombinant DNA technology. It has been produced in CHO cells and by affinity chromatography with peptide M.

As negative controls, InvivoGen provides antibody isotypes targeting *E. coli* β-galactosidase (β-Gal).

1. **Ahern E. et al., 2018.** Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. *Nat Rev Clin Oncol.* 15(11):676-693. 2. **Cheng ML. & Fong L., 2014.** Effects of RANKL-Targeted Therapy in Immunity and Cancer. *Front Oncol.* 3:329.

RELATED PRODUCTS

Product	Catalog Code
Anti-β-Gal-hIgA2 (Negative control)	bgal-mab7
Anti-hRANKL-hIgG1	hrankl-mab1
Anti-hRANKL-hIgG2 (Denosumab)	hrankl-mab2
pUNO1-hTRANCEa (gene for hRANKL)	puno1-htrancea

Isotype collections for other clinically relevant antibodies, such as Anti-hCD20 (Rituximab), Anti-hCTLA4 (Ipilimumab), Anti-hPD1 (Nivolumab) and Anti-HER2 (Trastuzumab) are also available.

For more information visit <https://www.invivogen.com/antibody-isotypes>.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com